title: Prognosis in primary effusion lymphoma is associated with the number of body cavities involved.
abstract: Primary effusion lymphoma (PEL) is a rare lymphoma associated with Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8), and characterized by a malignant body cavity effusion without solid organ or nodal involvement. Prognostic factors in patients with PEL have not been systematically studied. We conducted a literature search for patients with HHV8-positive PEL to identify potential prognostic factors for survival. Our search identified 147 patients, among which 104 patients were HHV8-positive. The median overall survival was 9 months. The median age was 57 years with a male predominance (6:1). Pathologically, 33% of the patients expressed CD20 and 69% expressed CD30. Patients with PEL with > 1 body cavity involved had a median overall survival (OS) of 4 months compared with 18 months in patients with only one cavity involved (p = 0.003). Additionally, in patients with one involved body cavity, pericardial involvement was associated with a longer median OS than pleural followed by peritoneal involvement (40, 27 and 5 months, respectively; p = 0.04). In conclusion, our study suggests that the number and location of body cavities involved are prognostic in patients with PEL.
authors.affiliation: Division of Hematology and Oncology, Department of Medicine, The Warren Alpert Medical School of Brown University and Rhode Island Hospital, Providence, RI, USA. jcastillo@lifespan.org
authors.forename: Jorge J
authors.initials: JJ
authors.lastname: Castillo
authors.forename: Helen
authors.initials: H
authors.lastname: Shum
authors.forename: Majid
authors.initials: M
authors.lastname: Lahijani
authors.forename: Eric S
authors.initials: ES
authors.lastname: Winer
authors.forename: James N
authors.initials: JN
authors.lastname: Butera
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018951:Antigens, CD20 / Q000378:metabolism; D005260:Female; D019288:Herpesvirus 8, Human / Q000302:isolation & purification* / Q000502:physiology; D054884:Host-Pathogen Interactions; D006801:Humans; D053208:Kaplan-Meier Estimate; D017730:Ki-1 Antigen / Q000378:metabolism; D054685:Lymphoma, Primary Effusion / Q000188:drug therapy / Q000473:pathology* / Q000821:virology; D008297:Male; D008875:Middle Aged; D010496:Pericardium / Q000187:drug effects / Q000473:pathology / Q000821:virology; D010529:Peritoneal Cavity / Q000473:pathology* / Q000821:virology; D035422:Pleural Cavity / Q000187:drug effects / Q000473:pathology* / Q000821:virology; D016066:Pleural Effusion, Malignant / Q000188:drug therapy / Q000473:pathology / Q000821:virology; D011379:Prognosis; D012196:Review Literature as Topic; D012737:Sex Factors
chemical_list: D018951:Antigens, CD20; D017730:Ki-1 Antigen